NCT00758069View on ClinicalTrials.gov

Clinical Study on Sitagliptin for Assessment of Glucose-lowering Effects (0431-045)

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

July 3, 2005

Primary Completion Date

February 13, 2006

Study Completion Date

February 13, 2006

Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
DRUG

sitagliptin phosphate

100 mg once daily (QD), taken orally for 4 weeks

DRUG

Comparator: Placebo

Placebo tablet, QD, taken orally for 4 weeks

DRUG

Comparator: Sitagliptin

50 mg twice daily (BID), taken orally for 4 weeks

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00758069 - Clinical Study on Sitagliptin for Assessment of Glucose-lowering Effects (0431-045) | Biotech Hunter | Biotech Hunter